Sanofi announced a global licensing agreement with Chia Tai Tianqing Pharmaceutical, a unit of Hong Kong‑listed Sino Biopharmaceutical, for rovadicitinib, a first‑in‑class JAK/ROCK inhibitor that received Chinese regulatory approval in February 2026 for myelofibrosis.
The deal values up to $1.53 billion, comprising a $135 million upfront payment and up to $1.395 billion in development, regulatory and sales milestones. Sanofi will hold exclusive worldwide rights to develop, commercialise and market the therapy.
Rovaticitinib’s dual mechanism positions it to treat both myelofibrosis and chronic graft‑versus‑host disease, with the FDA clearing a Phase 2 trial in the U.S. for cGVHD. The licensing expands Sanofi’s oncology portfolio and adds a high‑growth therapeutic area that complements its existing immuno‑oncology pipeline.
The transaction aligns with Sanofi’s broader strategy to strengthen its oncology and immunology businesses, following the 2025 acquisition of Blueprint Medicines. It also marks a significant out‑licensing milestone for Sino Biopharm, which has been pivoting from generic manufacturing to innovative drug development since 2018, with oncology accounting for 37.2 % of its revenue.
Market data show Sino Biopharm’s shares closed flat on the day of the announcement, indicating a muted immediate reaction. No analyst upgrades or downgrades were reported in connection with the deal.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.